Myriad Genetics Inc Total Liabilities
Myriad Genetics Inc total liabilities. Based on the latest financial reports, Myriad Genetics Inc (MYGN) has total liabilities worth $335.00 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Myriad Genetics Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Myriad Genetics Inc (1995–2025)
Total liabilities of Myriad Genetics Inc from 1995 to 2025. This chart illustrates how Myriad Genetics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore MYGN strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Myriad Genetics Inc Competitors by Total Liabilities
The table below lists competitors of Myriad Genetics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pinlive Foods Co Ltd
SHE:300892
|
China | CN¥241.21 Million |
|
Sophia Genetics SA
NASDAQ:SOPH
|
USA | $102.77 Million |
|
CJ Corp 4P Pref
KO:00104K
|
Korea | ₩30.66 Trillion |
|
PI Advanced Materials Co. Ltd
KQ:178920
|
Korea | ₩137.93 Billion |
|
Experian PLC
LSE:EXPN
|
UK | GBX8.71 Billion |
|
Virgin Galactic Holdings Inc
NYSE:SPCE
|
USA | $526.50 Million |
|
Ideal Group S.A
AT:INTEK
|
Greece | €717.20 Million |
|
Beijing InHand Networks Technology Co Ltd
SHG:688080
|
China | CN¥231.99 Million |
Liability Composition Analysis (1995–2025)
This chart breaks down Myriad Genetics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Myriad Genetics Inc balance sheet assets.
Liquidity & Leverage Metrics
Myriad Genetics Inc Total Liabilities Ratios Explained
Myriad Genetics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Myriad Genetics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Myriad Genetics Inc (1995–2025)
The table below shows the annual total liabilities of Myriad Genetics Inc from 1995 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $338.60 Million | +3.71% |
| 2024-12-31 | $326.50 Million | -10.13% |
| 2023-12-31 | $363.30 Million | +16.11% |
| 2022-12-31 | $312.90 Million | -11.33% |
| 2021-12-31 | $352.90 Million | -34.38% |
| 2020-12-31 | $537.80 Million | +13.51% |
| 2019-12-31 | $473.80 Million | +126.48% |
| 2018-12-31 | $209.20 Million | -52.55% |
| 2017-12-31 | $440.90 Million | +233.01% |
| 2016-12-31 | $132.40 Million | +27.19% |
| 2015-12-31 | $104.10 Million | -0.67% |
| 2014-12-31 | $104.80 Million | +39.31% |
| 2013-12-31 | $75.23 Million | +36.84% |
| 2012-12-31 | $54.98 Million | +24.84% |
| 2011-12-31 | $44.03 Million | +21.42% |
| 2010-12-31 | $36.27 Million | +12.74% |
| 2009-12-31 | $32.17 Million | -56.34% |
| 2008-12-31 | $73.69 Million | +109.47% |
| 2007-12-31 | $35.18 Million | +31.15% |
| 2006-12-31 | $26.82 Million | +15.19% |
| 2005-12-31 | $23.29 Million | +54.41% |
| 2004-12-31 | $15.08 Million | -22.01% |
| 2003-12-31 | $19.34 Million | -32.20% |
| 2002-12-31 | $28.52 Million | -12.47% |
| 2001-12-31 | $32.58 Million | +13.66% |
| 2000-12-31 | $28.67 Million | +430.90% |
| 1999-12-31 | $5.40 Million | -45.45% |
| 1998-12-31 | $9.90 Million | 0.00% |
| 1997-12-31 | $9.90 Million | +5.32% |
| 1995-12-31 | $9.40 Million | -- |
About Myriad Genetics Inc
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovar… Read more